 Kelly Knupp
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 23 | 2022 | 103 | 6.970 |
Why?
| | Anticonvulsants | 29 | 2023 | 179 | 6.380 |
Why?
| | Epilepsies, Myoclonic | 23 | 2024 | 41 | 6.080 |
Why?
| | Lennox Gastaut Syndrome | 6 | 2023 | 16 | 3.490 |
Why?
| | Epilepsy | 15 | 2024 | 278 | 3.070 |
Why?
| | Vigabatrin | 9 | 2022 | 18 | 2.710 |
Why?
| | Adrenocorticotropic Hormone | 7 | 2020 | 128 | 2.530 |
Why?
| | Seizures | 23 | 2024 | 340 | 1.990 |
Why?
| | Epilepsy, Generalized | 3 | 2023 | 13 | 1.200 |
Why?
| | Electroencephalography | 11 | 2023 | 362 | 1.160 |
Why?
| | Glucocorticoids | 3 | 2020 | 532 | 1.110 |
Why?
| | Drug Resistant Epilepsy | 4 | 2020 | 45 | 1.060 |
Why?
| | Cannabidiol | 4 | 2022 | 60 | 1.000 |
Why?
| | Plant Extracts | 4 | 2020 | 154 | 0.970 |
Why?
| | Fenfluramine | 7 | 2022 | 13 | 0.900 |
Why?
| | Infant | 30 | 2024 | 7964 | 0.890 |
Why?
| | Prednisolone | 4 | 2020 | 75 | 0.890 |
Why?
| | Developmental Disabilities | 4 | 2020 | 237 | 0.870 |
Why?
| | Genetic Therapy | 2 | 2023 | 257 | 0.860 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 29 | 0.760 |
Why?
| | Medical Marijuana | 2 | 2019 | 97 | 0.720 |
Why?
| | Child | 37 | 2023 | 18422 | 0.700 |
Why?
| | Dioxolanes | 2 | 2020 | 6 | 0.700 |
Why?
| | Child, Preschool | 23 | 2024 | 9119 | 0.650 |
Why?
| | Status Epilepticus | 4 | 2022 | 32 | 0.620 |
Why?
| | Humans | 68 | 2024 | 114709 | 0.620 |
Why?
| | Precision Medicine | 1 | 2021 | 337 | 0.590 |
Why?
| | Leukomalacia, Periventricular | 1 | 2017 | 7 | 0.580 |
Why?
| | Thyrotropin | 1 | 2017 | 99 | 0.570 |
Why?
| | Treatment Outcome | 16 | 2022 | 9088 | 0.540 |
Why?
| | Cannabis | 3 | 2020 | 384 | 0.530 |
Why?
| | Infant, Premature, Diseases | 1 | 2017 | 89 | 0.520 |
Why?
| | Treatment Failure | 1 | 2016 | 331 | 0.500 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 286 | 0.500 |
Why?
| | Perception | 1 | 2017 | 311 | 0.480 |
Why?
| | Disease Progression | 2 | 2021 | 2381 | 0.460 |
Why?
| | Testosterone | 1 | 2017 | 343 | 0.460 |
Why?
| | Unverricht-Lundborg Syndrome | 1 | 2014 | 1 | 0.450 |
Why?
| | Lafora Disease | 1 | 2014 | 2 | 0.450 |
Why?
| | Male | 37 | 2023 | 55609 | 0.450 |
Why?
| | Physicians | 1 | 2021 | 772 | 0.440 |
Why?
| | Administration, Oral | 5 | 2019 | 728 | 0.440 |
Why?
| | Epilepsy, Absence | 2 | 2023 | 4 | 0.440 |
Why?
| | Myoclonus | 2 | 2023 | 13 | 0.430 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1395 | 0.430 |
Why?
| | Adolescent | 19 | 2022 | 17855 | 0.420 |
Why?
| | Female | 38 | 2023 | 59523 | 0.420 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 497 | 0.400 |
Why?
| | Hypertension | 1 | 2019 | 1056 | 0.380 |
Why?
| | Prospective Studies | 11 | 2023 | 6220 | 0.380 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 4 | 2023 | 15 | 0.380 |
Why?
| | Cost of Illness | 3 | 2018 | 254 | 0.380 |
Why?
| | Parents | 3 | 2022 | 1186 | 0.370 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 338 | 0.370 |
Why?
| | Coronavirus Infections | 3 | 2020 | 330 | 0.370 |
Why?
| | Dronabinol | 3 | 2022 | 118 | 0.340 |
Why?
| | Epileptic Syndromes | 4 | 2024 | 66 | 0.340 |
Why?
| | Pandemics | 4 | 2022 | 1320 | 0.320 |
Why?
| | Executive Function | 2 | 2024 | 380 | 0.320 |
Why?
| | Caregivers | 4 | 2024 | 717 | 0.310 |
Why?
| | Cannabinoids | 2 | 2022 | 115 | 0.310 |
Why?
| | Genetic Testing | 2 | 2023 | 381 | 0.300 |
Why?
| | Retrospective Studies | 12 | 2023 | 12556 | 0.290 |
Why?
| | Cohort Studies | 6 | 2018 | 4895 | 0.260 |
Why?
| | Headache | 1 | 2006 | 133 | 0.240 |
Why?
| | Migraine Disorders | 1 | 2006 | 82 | 0.240 |
Why?
| | Delivery of Health Care | 3 | 2020 | 833 | 0.240 |
Why?
| | Analgesics | 1 | 2006 | 158 | 0.240 |
Why?
| | Comorbidity | 2 | 2019 | 1448 | 0.220 |
Why?
| | Epilepsy, Reflex | 1 | 2023 | 1 | 0.220 |
Why?
| | Family | 2 | 2018 | 589 | 0.220 |
Why?
| | Double-Blind Method | 3 | 2022 | 1660 | 0.210 |
Why?
| | Betacoronavirus | 3 | 2020 | 250 | 0.210 |
Why?
| | Cosyntropin | 1 | 2022 | 4 | 0.200 |
Why?
| | Spasm | 1 | 2022 | 19 | 0.200 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.190 |
Why?
| | Benzazepines | 2 | 2018 | 37 | 0.190 |
Why?
| | Delayed Diagnosis | 1 | 2021 | 70 | 0.190 |
Why?
| | Dependovirus | 1 | 2021 | 52 | 0.190 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 100 | 0.180 |
Why?
| | KCNQ2 Potassium Channel | 1 | 2020 | 4 | 0.180 |
Why?
| | Shab Potassium Channels | 1 | 2020 | 18 | 0.180 |
Why?
| | Young Adult | 5 | 2022 | 10472 | 0.170 |
Why?
| | Standard of Care | 1 | 2020 | 62 | 0.170 |
Why?
| | Internationality | 1 | 2020 | 143 | 0.170 |
Why?
| | Mutation | 3 | 2023 | 3346 | 0.170 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 412 | 0.160 |
Why?
| | Causality | 1 | 2019 | 103 | 0.160 |
Why?
| | Animals | 6 | 2021 | 31709 | 0.160 |
Why?
| | Eyelids | 3 | 2023 | 29 | 0.160 |
Why?
| | Sleep | 3 | 2021 | 632 | 0.160 |
Why?
| | Hormones | 1 | 2019 | 132 | 0.160 |
Why?
| | United States | 7 | 2019 | 12186 | 0.160 |
Why?
| | Health Surveys | 2 | 2018 | 443 | 0.160 |
Why?
| | Drug Approval | 1 | 2019 | 78 | 0.160 |
Why?
| | Infant, Newborn | 6 | 2023 | 5047 | 0.150 |
Why?
| | Health Care Surveys | 1 | 2020 | 539 | 0.150 |
Why?
| | Phenobarbital | 1 | 2018 | 17 | 0.150 |
Why?
| | Incidence | 2 | 2019 | 2313 | 0.150 |
Why?
| | Sickness Impact Profile | 1 | 2018 | 50 | 0.150 |
Why?
| | Urine | 1 | 2017 | 54 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4624 | 0.140 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 3 | 0.140 |
Why?
| | Brain | 3 | 2018 | 2371 | 0.140 |
Why?
| | Body Height | 1 | 2017 | 180 | 0.140 |
Why?
| | Employment | 1 | 2018 | 137 | 0.130 |
Why?
| | Consensus | 3 | 2023 | 539 | 0.130 |
Why?
| | Heterozygote | 1 | 2017 | 251 | 0.130 |
Why?
| | Neuroimaging | 1 | 2018 | 249 | 0.130 |
Why?
| | Adult | 6 | 2022 | 30554 | 0.130 |
Why?
| | Benzimidazoles | 1 | 2017 | 138 | 0.130 |
Why?
| | Plasma | 1 | 2017 | 211 | 0.130 |
Why?
| | Intellectual Disability | 1 | 2017 | 128 | 0.130 |
Why?
| | Telemedicine | 2 | 2020 | 662 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1121 | 0.120 |
Why?
| | Serotonin | 1 | 2017 | 292 | 0.120 |
Why?
| | Neurology | 3 | 2020 | 85 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2018 | 4411 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 381 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 811 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2018 | 490 | 0.110 |
Why?
| | Nervous System Diseases | 1 | 2017 | 256 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2015 | 152 | 0.110 |
Why?
| | Infant, Premature | 1 | 2017 | 476 | 0.110 |
Why?
| | Body Weight | 1 | 2017 | 869 | 0.110 |
Why?
| | Colorado | 2 | 2019 | 4100 | 0.110 |
Why?
| | Quality of Life | 3 | 2018 | 2353 | 0.100 |
Why?
| | Mental Health | 1 | 2018 | 562 | 0.100 |
Why?
| | Communication | 3 | 2024 | 744 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 681 | 0.100 |
Why?
| | Pentobarbital | 1 | 2011 | 16 | 0.100 |
Why?
| | Age of Onset | 3 | 2018 | 446 | 0.100 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 90 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 928 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 585 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 1820 | 0.090 |
Why?
| | Neurologists | 2 | 2021 | 18 | 0.090 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 134 | 0.090 |
Why?
| | Piracetam | 1 | 2010 | 15 | 0.090 |
Why?
| | Limit of Detection | 2 | 2022 | 53 | 0.090 |
Why?
| | Prevalence | 1 | 2016 | 2251 | 0.080 |
Why?
| | Forecasting | 2 | 2024 | 330 | 0.080 |
Why?
| | Health Resources | 2 | 2020 | 122 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 951 | 0.060 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2005 | 54 | 0.060 |
Why?
| | Oxytocin | 1 | 2005 | 45 | 0.060 |
Why?
| | Maternal Behavior | 1 | 2005 | 70 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1430 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2006 | 1342 | 0.060 |
Why?
| | Disease Management | 2 | 2020 | 560 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2015 | 2128 | 0.060 |
Why?
| | Signal Transduction | 1 | 2017 | 4516 | 0.060 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2004 | 2 | 0.060 |
Why?
| | Hyalin | 1 | 2004 | 5 | 0.060 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2004 | 3 | 0.060 |
Why?
| | Wechsler Scales | 1 | 2024 | 52 | 0.060 |
Why?
| | Aggression | 1 | 2005 | 183 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2020 | 3053 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 8634 | 0.050 |
Why?
| | Rectum | 1 | 2004 | 153 | 0.050 |
Why?
| | Pediatrics | 2 | 2020 | 981 | 0.050 |
Why?
| | Eosinophils | 1 | 2004 | 278 | 0.050 |
Why?
| | Health Services | 1 | 2021 | 103 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 347 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2020 | 4410 | 0.040 |
Why?
| | Tuberous Sclerosis | 1 | 2020 | 36 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 57 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 197 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 102 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 141 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 119 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 532 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 122 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 286 | 0.040 |
Why?
| | Drug Resistance | 1 | 2019 | 158 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 287 | 0.040 |
Why?
| | Gene Ontology | 1 | 2018 | 46 | 0.040 |
Why?
| | Neurologic Examination | 2 | 2011 | 114 | 0.040 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 2 | 0.040 |
Why?
| | Waiting Lists | 1 | 2019 | 211 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 18 | 0.040 |
Why?
| | Agenesis of Corpus Callosum | 1 | 2017 | 12 | 0.040 |
Why?
| | Efficiency | 1 | 2018 | 84 | 0.040 |
Why?
| | Medicaid | 1 | 2021 | 407 | 0.040 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2017 | 23 | 0.040 |
Why?
| | Muscle Hypotonia | 1 | 2017 | 31 | 0.040 |
Why?
| | Drug Costs | 1 | 2018 | 92 | 0.030 |
Why?
| | Receptors, Serotonin | 1 | 2017 | 32 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 2017 | 95 | 0.030 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2017 | 67 | 0.030 |
Why?
| | Income | 1 | 2018 | 167 | 0.030 |
Why?
| | Microcephaly | 1 | 2017 | 51 | 0.030 |
Why?
| | Delphi Technique | 1 | 2017 | 160 | 0.030 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 216 | 0.030 |
Why?
| | Larva | 1 | 2017 | 194 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2018 | 239 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 470 | 0.030 |
Why?
| | RNA Splicing | 1 | 2017 | 245 | 0.030 |
Why?
| | Cognition | 1 | 2022 | 989 | 0.030 |
Why?
| | Central Nervous System | 1 | 2017 | 235 | 0.030 |
Why?
| | Gestational Age | 1 | 2018 | 760 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1204 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 259 | 0.030 |
Why?
| | Zebrafish | 1 | 2017 | 412 | 0.030 |
Why?
| | Sex Factors | 1 | 2017 | 1715 | 0.030 |
Why?
| | Genetic Variation | 1 | 2017 | 870 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 801 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 1890 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3330 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 371 | 0.020 |
Why?
| | Kidney | 1 | 2017 | 1188 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 198 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1134 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 2797 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2087 | 0.020 |
Why?
| | Hospitalization | 1 | 2018 | 1752 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2508 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 26738 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 911 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 3535 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2286 | 0.020 |
Why?
| | Nalidixic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Naphthyridines | 1 | 2005 | 16 | 0.020 |
Why?
| | Fluoxetine | 1 | 2005 | 46 | 0.020 |
Why?
| | Drug Synergism | 1 | 2005 | 317 | 0.010 |
Why?
| | Aged | 1 | 2022 | 19074 | 0.010 |
Why?
| | Submucous Plexus | 1 | 2004 | 2 | 0.010 |
Why?
| | Myenteric Plexus | 1 | 2004 | 4 | 0.010 |
Why?
| | Consanguinity | 1 | 2004 | 46 | 0.010 |
Why?
| | Postpartum Period | 1 | 2005 | 278 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2005 | 458 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1842 | 0.010 |
Why?
| | Ultrasonography | 1 | 2004 | 634 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2218 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1036 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6116 | 0.010 |
Why?
| | Rats | 1 | 2005 | 4958 | 0.010 |
Why?
| | Neurons | 1 | 2004 | 1280 | 0.010 |
Why?
| | Pregnancy | 1 | 2005 | 5520 | 0.010 |
Why?
|
|
Knupp's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|